Psyence Biomedical Ltd.
PBM
$0.73
-$0.03-3.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.89% | 59.36% | 105.04% | 88.45% | 71.97% |
| Depreciation & Amortization | 138.10% | 327.27% | 2,050.00% | 3,100.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.32% | 68.54% | 75.46% | 27.57% | -2.49% |
| Operating Income | -30.32% | -68.54% | -75.46% | -27.57% | 2.49% |
| Income Before Tax | 92.28% | 94.21% | 99.35% | 11.19% | -1,204.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.28% | 94.21% | 99.35% | 11.19% | -1,204.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.28% | 94.21% | 99.35% | 11.19% | -1,204.77% |
| EBIT | -30.32% | -68.54% | -75.46% | -27.57% | 2.49% |
| EBITDA | -30.25% | -81.59% | -198.84% | -463.62% | -- |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |